EC approves Ordspono for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission

Merck receives EC approval for Winrevair for treatment of PAH

Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Pfizer launches digital platform ‘PfizerForAll’

PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care

Merck announces Phase 3 trial initiation for Bomedemstat

The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience

Akums Q1 FY25 revenue up 5.1%

The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually

Royal Sense launches stergic dengue IgG/IgM rapid test

The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples

Alembic receives FDA final approval for Betamethasone Valerate Foam, 0.12%